Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) shares were up 2.7% during mid-day trading on Monday . The company traded as high as $96.45 and last traded at $96.42, with a volume of 987,389 shares changing hands. The stock had previously closed at $93.89.

A number of research analysts recently issued reports on VRTX shares. Leerink Swann restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Thursday, April 28th. Vetr upgraded Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $94.50 price target on the stock in a report on Monday, June 27th. Jefferies Group restated a “buy” rating and set a $103.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, June 17th. Piper Jaffray Cos. restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Saturday, June 18th. Finally, HC Wainwright restated a “buy” rating and set a $155.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, April 28th. Eight equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Vertex Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $123.11.

The company has a 50 day moving average of $89.13 and a 200-day moving average of $87.50. The company’s market capitalization is $23.79 billion.

In related news, Director Joshua S. Boger sold 5,130 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, May 4th. The shares were sold at an average price of $81.02, for a total transaction of $415,632.60. Following the transaction, the director now directly owns 270,414 shares of the company’s stock, valued at $21,908,942.28. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Paul M. Silva sold 3,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $87.63, for a total transaction of $262,890.00. Following the transaction, the senior vice president now directly owns 15,950 shares in the company, valued at $1,397,698.50. The disclosure for this sale can be found here.

Other institutional investors have modified their holdings of the company. Ameritas Investment Partners Inc. raised its position in shares of Vertex Pharmaceuticals by 0.9% in the fourth quarter. Ameritas Investment Partners Inc. now owns 8,698 shares of the pharmaceutical company’s stock valued at $1,094,000 after buying an additional 78 shares during the last quarter. Turner Investments L.P. acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at about $1,095,000. Robeco Institutional Asset Management B.V. raised its position in shares of Vertex Pharmaceuticals by 32.1% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 10,728 shares of the pharmaceutical company’s stock valued at $1,350,000 after buying an additional 2,605 shares during the last quarter. Greenwood Capital Associates LLC raised its position in shares of Vertex Pharmaceuticals by 0.7% in the fourth quarter. Greenwood Capital Associates LLC now owns 10,768 shares of the pharmaceutical company’s stock valued at $1,355,000 after buying an additional 80 shares during the last quarter. Finally, Suntrust Banks Inc. acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at about $1,944,000.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.